Geoffrey Purtill - 20 Feb 2023 Form 4 Insider Report for INVACARE CORP

Role
President and CEO
Signature
/s/ Geoffrey Purtill, by Kristofer K. Spreen, his attorney-in-fact, pursuant to Power of Attorney dated November 24, 2021, on file with the Commission
Issuer symbol
N/A
Transactions as of
20 Feb 2023
Net transactions value
$0
Form type
4
Filing time
28 Feb 2023, 16:57:42 UTC
Previous filing
15 Sep 2022
Next filing
24 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IVC Common Shares Disposed to Issuer $0 -1,666 -1.1% $0.000000 156,086 20 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IVC Employee Stock Option (Right to Buy) 22,611 20 Feb 2023 Common Shares 22,611 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person forfeited 1,666 restricted stock units back to the issuer.
F2 Includes 7,439 previously reported restricted stock units issued pursuant to the Invacare Corporation 2018 Equity Compensation Plan. 1,425 of these restricted stock units vest in full on May 15, 2023; 2,680 of these restricted stock units vest in 1/2 increments on May 15, 2023 and May 15, 2024; and 3,334 of these restricted stock units vest equally on November 15, 2023 and November 15, 2024, subject to the reporting person's continued service with the company.
F3 No transaction is being reported on this line. Reported on previously filed Form 3.
F4 The reporting person holds previously reported options to buy 22,611 Common Shares (with tandem tax withholding rights) under the Invacare Corporation 2003 Performance Plan and the Invacare Corporation 2013 Equity Compensation Plan, granted in reliance upon the exemption provided by Rule 16b-3. All options were granted between March 18, 2013 and March 16, 2017, at exercise prices between $12.15 and $14.49 per share, will expire between March 18, 2023 and March 16, 2027, and became exercisable between May 15, 2014 and December 31, 2019.
F5 The current balance reflects the expiration of 3,300 options on August 14, 2022.